LIVAZO

This brand name is authorized in Germany, Spain, Ireland, Poland

Active ingredients

The drug LIVAZO contains one active pharmaceutical ingredient (API):

1 Pitavastatin UNII IYD54XEG3W - PITAVASTATIN CALCIUM

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver. Read about Pitavastatin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIVAZO Film-coated tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AA08	Pitavastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 11613906, 11613912, 11613929
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 5324538, 5324538IP, 5324553, 73037, 73038, 73039
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100249908, 100249914, 100249920